Arcus Biosciences Announces Participation at Two Investor Conferences in September
August 22 2018 - 4:05PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced the Company will be participating
in the following upcoming investor conferences:
- Citi's 13th Annual Biotech Conference
in Boston on Wednesday, September 5, 2018. At 3:15 pm ET, Terry
Rosen, Ph.D., Chief Executive Officer, will participate in a panel
discussion entitled, "Targeted Therapies Oncology – Aiming for the
Bull’s Eye."
- Morgan Stanley 16th Annual Global
Healthcare Conference in New York City on Thursday, September 13,
2018. At 4:40 pm ET, Terry Rosen, Ph.D., Chief Executive Officer,
and Jennifer Jarrett, Chief Operating Officer and Chief Financial
Officer, will participate in a fireside chat. Individuals may
access the live audio webcast of the fireside chat by visiting the
“Events & Presentations” section of the Company’s website at
https://investors.arcusbio.com/investors/events-and-presentations.
A replay of the webcast will be available for 30 days following the
live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist AB928, which is in a
Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in
IND-enabling studies. Arcus has extensive in-house expertise
in medicinal chemistry, immunology, biochemistry, pharmacology and
structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180822005094/en/
Arcus BiosciencesJennifer Jarrett,
510-694-6261jjarrett@arcusbio.comorNicole Arndt,
510-284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2023 to Apr 2024